Institutet för Hälso- och
Sjukvårdsekonomi
Box 2127
SE-220 02 Lund
Besök: Råbygatan 2
Tel: 046-32 91 00
ihe[at]ihe.se

Lindgren Peter
med dr | projektledare

Arbetsområden
Peter Lindgren, med. dr, är forskningsledare vid IHE och adjungerad docent i hälsoekonomi vid Institutionen för lärande, informatik, management och etik vid Karolinska Institutet.

Peter är i grunden civilingenjör i datateknik med en examen från KTH. 2005 disputerade han vid Karolinska Institutet med avhandlingen ”Modelling the economics of prevention.” Han bidrog till att etablera Stockholm Health Economics (senare European Health Economics) som en ledande aktör inom hälsoekonomisk konsultverksamhet och var VD mellan 2003 och 2007. Då bolaget köptes av i3 Innovus (en del av Ingenix, senare OptumInsight) blev han ansvarig för verksamheten inom kardiovaskulär medicin och metabola sjukdomar och senior fellow vid Ingenix. 2011 – 2012 var han Vice President för hälsoekonomiverksamheten i Sverige och Tyskland. Mellan 2013 och 2015 var Peter forskningschef vid Ivbar, ett FoU-bolag med fokus på värdebaserad styrning av hälso- och sjukvård.

Peter har ett brett intresse inom hälsoekonomi och beröringsfältet mellan hälsoekonomi, hälso- och sjukvård och epidemiologi. Han har lett och deltagit i ett stort antal olika forskningsprojekt inom flera olika terapiområden, resulterande i mer än 70 publikationer.

Urval av publiceringar

Lindgren P, Jönsson & Wilking N
Assessment of value for resource allocation in cancer care
Journal of Cancer Policy 2017 11: 12-18

Cole A, Lundqvist A, Lorgelly P, Norrlid H, Karlsberg Schaffer S, Lewis F, Hernandez-Villafuerte K, Lindgren P, Garau M, Welin K-O, Bianchi S, Althin R, O’Neill P, Persson U, and Towse A
Improving Efficiency and Resource Allocation in Future Cancer Care
London, UK: OHE-IHE Consulting Report, September 2016

Jönsson B, Hofmarcher T, Lindgren P & Wilking N
The cost and burden of cancer in the European Union 1995-2014
Eur J Cancer. 2016 Aug 30;66:162-170. 

Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, et al.
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Clin Cardiol. 2016;39(6):313-20. Clin Cardiol. 2016 Jun;39(6):313-20

Landfeldt E, Lindgren P, Bell CF, Guglieri M, Straub V, Lochmuller H, et al.
Quantifying the burden of caregiving in Duchenne muscular dystrophy
J Neurol. 2016 May;263(5):906-15

Landfeldt E, Lindgren P, Bell CF, Guglieri M, Straub V, Lochmuller H, et al.
Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study
Dev Med Child Neurol. 2016;58(5):508-15

Mesterton J, Lindgren P, Ekenberg Abreu A, Ladfors L, Lilja M, Saltvedt S, et al.
Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study
BMC Pregnancy Childbirth. 2016;16(1):125

Jönsson B, Hofmarcher T, Lindgren P & Wilking N
Comparator report on patient access to cancer medicines in Europe revisited
Lund: IHE Report 2016:4

Berg J, Lindgren P, Mejhert M, Edner M, Dahlström U & Kahan T
Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry
Value Health. 2015 Jun; 18(4): 439-48.
PMID: 26091598


Journath G, Hammar N, Elofsson S, Linnersjo A, Vikstrom M, Walldius G, Lindgren P et al.
Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden.
PloS one. 2015; 10(11):e0140201

Landfeldt E, Mayhew A, Eagle M, Lindgren P, Bell CF, Guglieri M, et al.
Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT).
Neuromuscul Disord. 2015; 25(12): 937-44

Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al.
Compliance to Care Guidelines for Duchenne Muscular Dystrophy.
Journal of Neuromuscular Diseases. 2015; 2(1): 63-72

Lindgren, P., Ersättning i sjukvården. Modeller, effekter och rekommendationer. 2014, Stockholm: SNS Förlag.

Salaj, P., Kubes, R., Cetkovsky, P., Capova, I., Penka, M., Ovesna, P., Mesterton, J. and Lindgren, P. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry. Thromb Res, 2014. 133(2): p. 162-7

Landfeldt, E., Lindgren, P., Bell, C.F., Schmitt, C., Guglieri, M., Straub, V., Lochmuller, H. and Bushby, K. The burden of Duchenne muscular dystrophy: An international, cross-sectional study. Neurology, 2014

Reynolds, M.R., Nilsson, J., Akerborg, O., Jhaveri, M. and Lindgren, P. Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model. Clinicoecon Outcomes Res, 2013. 5: p. 19-28.3544268

Nilsson, J., Akerborg, O., Bego-Le Bagousse, G., Rosenquist, M. and Lindgren, P. Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation-results for Canada, Italy, Sweden and Switzerland. Eur J Health Econ, 2013. 14(3): p. 481-93

Mejhert, M., Lindgren, P., Schill, O., Edner, M., Persson, H. and Kahan, T. Long term health care consumption and cost expenditure in systolic heart failure. Eur J Intern Med, 2013. 24(3): p. 260-5

Berg, J., Sauriol, L., Connolly, S. and Lindgren, P. Cost-Effectiveness of Dronedarone in Patients With Atrial Fibrillation in the ATHENA Trial. Can J Cardiol, 2013. 29(10): p. 1249-55

Åkerborg, Ö., Nilsson, J., Bascle, S., Lindgren, P. and Reynolds, M. Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. Clin Ther, 2012. 34(8): p. 1788-802

Lindgren, P. and Jonsson, B. Cost-effectiveness of statins revisited: lessons learned about the value of innovation. European Journal of Health Economics, 2012. 13(4): p. 445-450

Ekman, M., Lindgren, P., Miltenburger, C., Meier, G., Locklear, J.C. and Chatterton, M.L. Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode. Pharmacoeconomics, 2012. 30(6): p. 513-530

Kasteng, F., Eriksson, J., Sennfalt, K. and Lindgren, P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatrica Scandinavica, 2011. 124(3): p. 214-225

Holstenson, E., Ringborg, A., Lindgren, P., Coste, F., Diamand, F., Nieuwlaat, R. and Crijns, H. Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace, 2011. 13(1): p. 23-30

Ringborg, A., Lindgren, P., Yin, D.D., Martinell, M. and Stalhammar, J. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes & Metabolism, 2010. 36(3): p. 198-203

Lindgren, P., Eriksson, J., Buxton, M., Kahan, T., Poulter, N.R., Dahlof, B., Sever, P.S., Wedel, H., Jonsson, B. and Investigators, A.T. The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial. International Journal of Clinical Practice, 2010. 64(9): p. 1228-1234
© IHE 2017